Key takeaways
- • Trial: SURMOUNT-4 (NCT04660643) — Phase 3, 670 participants over 88 weeks.
- • Drug studied: Zepbound (Tirzepatide) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from week 36 to week 88 after open-label tirzepatide run-in (withdrawal design)
- • Key result: Continued tirzepatide arm lost additional 5.5%; placebo-switched arm regained 14.0% (between-group difference -19.4 percentage points)
- • Published: JAMA, 2024.
Study design
SURMOUNT-4 was a phase 3 randomized controlled trial enrolling 670 participants over 88 weeks. The trial studied Zepbound (Tirzepatide) for obesity / overweight and was published in JAMA in 2024.
Primary endpoint
Percent change in body weight from week 36 to week 88 after open-label tirzepatide run-in (withdrawal design)
Key results
| Measure | Value |
|---|---|
| Headline result | Continued tirzepatide arm lost additional 5.5%; placebo-switched arm regained 14.0% (between-group difference -19.4 percentage points) |
| Participants | 670 |
| Duration | 88 weeks |
| Phase | Phase 3 |
Citation
SURMOUNT-4. Published in JAMA, 2024.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Zepbound drug page — pricing, FDA status, side effects, alternatives
- All tirzepatide trials
- GLP-1 clinical trials database
Other Zepbound trials
- SURMOUNT-1 — Mean weight loss 15
- SURMOUNT-2 — Mean weight loss 12
- SURMOUNT-3 — Additional 18
Other Tirzepatide trials
- SURPASS-1 (Mounjaro) — HbA1c reduction 1
- SURPASS-2 (Mounjaro) — HbA1c reduction 2
- SURPASS-3 (Mounjaro) — HbA1c reduction 1
- SURPASS-4 (Mounjaro) — HbA1c reduction 2
Important: This trial was conducted on the FDA-approved branded product Zepbound. Compounded versions of Tirzepatide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.